Patents Examined by Gigi G Huang
-
Patent number: 11987597Abstract: Provided herein are inhibitors of TNF-?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-? inhibitory compounds for the treatment of diseases or disorders.Type: GrantFiled: September 21, 2023Date of Patent: May 21, 2024Assignee: FORWARD THERAPEUTICS, INC.Inventor: Toufike Kanouni
-
Patent number: 11931411Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: November 10, 2021Date of Patent: March 19, 2024Assignees: DBV Technologies, Assistance Pulique-Hoôpitaux De Paris, Université de Paris CitéInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Patent number: 11882828Abstract: The present inventions concerns use of a certain methoxyacrylate compound to control mosquitoes, and vector control solutions comprising a defined methoxyacrylate compound, in particular the invention relates to a substrate, to a composition, for controlling mosquitoes comprising a defined methoxyacrylate compound, and to certain methoxyacrylate compounds.Type: GrantFiled: May 31, 2016Date of Patent: January 30, 2024Assignee: SYNGENTA PARTICIPATIONS AGInventors: Ottmar Franz Hueter, Natalie Anne Miller, Philip Wege, Mark Hoppe, Peter Maienfisch, Michael Drysdale Turnbull
-
Patent number: 11839616Abstract: The disclosure provides, inter alia, topical pharmaceutical compositions comprising active agents, methods for increasing tear production using the topical pharmaceutical compositions, and methods for treating dry eye disorders using the topical pharmaceutical compositions.Type: GrantFiled: August 24, 2018Date of Patent: December 12, 2023Assignee: The Regents of the University of CaliforniaInventors: Alan S. Verkman, Marc H. Levin
-
Patent number: 11786518Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.Type: GrantFiled: March 20, 2020Date of Patent: October 17, 2023Assignee: Aldeyra Therapeutics, Inc.Inventors: David Clark, Susan Macdonald, Stephen Gitu Machatha, Lise Lund Kjems
-
Patent number: 11679106Abstract: Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. In some embodiments, the pharmaceutical composition further comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.Type: GrantFiled: May 9, 2020Date of Patent: June 20, 2023Assignee: Celgene Quanticel Research, Inc.Inventors: Juan Manual Betancort, Jeffrey Alan Stafford, Ryan Stansfield, James Marvin Veal
-
Patent number: 11666533Abstract: Compositions comprising a therapeutically effective amount of a multikinase inhibitor, such as nintedanib or axitinib or pazopanib, are provided, wherein the composition is an emulsion, such as a nanoemulsion, with lipophilic carrier (e.g., castor oil), a polyoxyl oil (e.g., polyolyl-35 castor oil), optionally with a surfactant (e.g., polysorbate 80), optionally with a cyclic oligosaccharide, such as a cyclodextrin (e.g., 2-hydroxypropyl-beta-cyclodextrin), as a solubilizer. Methods for treating ocular conditions with the compositions are also provided.Type: GrantFiled: October 25, 2021Date of Patent: June 6, 2023Assignee: Cloudbreak Therapeutics, LLCInventors: Jinsong Ni, Van Dinh, Walter Tien
-
Patent number: 11654123Abstract: This invention provides a composition comprising Formula I, or salt thereof, wherein X is chlorine, Y is a methyl group, and R is an alkyl group having a carbon chain length of three carbon atoms. A method of inhibiting osteoclast development and a method for preventing bone erosion in a patient using the compositions of Formula I are disclosed.Type: GrantFiled: May 20, 2020Date of Patent: May 23, 2023Assignees: West Virginia University, University of Pittsburgh—Of the Commonwealth System of Higher Education, Temple University—Of the Commonwealth System of Higher EducationInventors: John B. Barnett, Harry C. Blair, Jonathan Soboloff
-
Patent number: 11583535Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: GrantFiled: August 20, 2020Date of Patent: February 21, 2023Assignee: OCCURX PTY LTDInventors: Darren James Kelly, David Stapleton
-
Patent number: 11529309Abstract: Provided herein are fluorinated compounds having chemical structures: (I) where n is 0 or greater, or (II) where m and n are 0 or greater, or an amino acid, a soluble polymer, an oligo(ethylene glycol), a poly(ethylene glycol), or a carbohydrate each fluorinated with perfluorocarbons having the chemical structure (III) where n is 0 or greater. These fluorinated compounds are utilized in contact lenses to impart lipid-resistant, protein-resistant and biofouling-resistant properties, thus reducing discomfort and infection caused by contact lens wear without changing its transmission characteristics. Also provided is an ophthalmic drug delivery system comprising at least one of the compounds described above embedded in the contact lens and a kit to incorporate the ophthalmic into a contact lens. Methods for incorporating these compounds onto a contact lens without affecting transparency and for use in treating an ophthalmologic-associated condition are provided.Type: GrantFiled: April 28, 2017Date of Patent: December 20, 2022Assignee: UNIVERSITY OF HOUSTON SYSTEMInventors: Guoting Qin, Chengzhi Cai
-
Patent number: 11529333Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.Type: GrantFiled: March 15, 2019Date of Patent: December 20, 2022Assignee: AZURITY PHARMACEUTICALS, INC.Inventors: Swati Nagar, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Sandeep Pal
-
Patent number: 11491255Abstract: Film forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film-forming polymer, a tackifier, and a volatile solvent. The film forming gels can also include antiseptics, cationic polymer coagulants, fillers, and other additives. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing.Type: GrantFiled: April 4, 2016Date of Patent: November 8, 2022Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Delony L. Langer-Anderson, George W. Griesgraber, Semra Colak Atan, Junia M. Pereira, Katie F. Wlaschin, Alexi J. Young, Robert A. Asmus, Petra L. Kohler Riedi, David S. Hays, Jerald K. Rasmussen, Michael J. Solberg
-
Patent number: 11478456Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.Type: GrantFiled: March 15, 2022Date of Patent: October 25, 2022Assignee: AZURITY PHARMACEUTICALS, INC.Inventors: Swati Nagar, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Sandeep Pal
-
Patent number: 11464781Abstract: Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.Type: GrantFiled: February 24, 2010Date of Patent: October 11, 2022Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Robert Davis, Allen Fienberg
-
Patent number: 11464766Abstract: The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.Type: GrantFiled: September 17, 2019Date of Patent: October 11, 2022Assignee: SEN-JAM PHARMACEUTICAL LLCInventors: Jacqueline M. Iversen, James M. Iversen
-
Patent number: 11433044Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.Type: GrantFiled: March 7, 2019Date of Patent: September 6, 2022Assignee: scPharmaceuticals Inc.Inventors: Scott A. Michaels, Pieter Muntendam, Glenn R. Larsen
-
Patent number: 11426346Abstract: A lutein-containing ophthalmic composition, wherein the ophthalmic composition is mainly consisting of a natural anti-inflammatory substance, a substance with increasing liquid viscosity, and an artificial tear. The substance with increasing liquid viscosity could apply the ophthalmic composition to elongate the retention time on the ocular surface, thereby increasing the retention time of anti-inflammatory substance on the ocular surface for treating dry eye syndrome and inhibiting ocular surface inflammation.Type: GrantFiled: October 13, 2019Date of Patent: August 30, 2022Assignee: TAIPEI MEDICAL UNIVERSITYInventors: Ching-Li Tseng, I-Chan Lin, Yi-Zhou Chen, Yu-Lun Chuang, Cheng-Han Tsai, Zhi-Yu Chen
-
Patent number: 11413304Abstract: The present invention relates to a drop-forming, storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that it is emulsifier-free as well as buffer-free and comprises hyaluronic acid and/or hyaluronate.Type: GrantFiled: April 12, 2017Date of Patent: August 16, 2022Assignee: DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBHInventors: Günther Bellman, Lutz Kröhne
-
Patent number: 11406713Abstract: Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.Type: GrantFiled: March 17, 2014Date of Patent: August 9, 2022Assignee: XORTX THERAPEUTICS, INC.Inventor: Allen Davidoff
-
Patent number: 11376214Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.Type: GrantFiled: April 30, 2020Date of Patent: July 5, 2022Assignee: KIORA PHARMACEUTICALS, INC.Inventors: Brenda K. Mann, Hee-Kyoung Lee